Navigation Links
Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative alpha particle immunotherapeutics, is pleased to announce that Mr. Jack Talley , Actinium's President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference on Monday, February 11th at 10:15 AM EST.  Mr. Talley will provide an overview of the Company and its corporate activities. The logistics and webcast information are shown below.

Details Of The Event

Date: February 11, 2013

Time: 10:15 AM EST

Location: Park South, 4th Floor; Waldorf Astoria Hotel; New York, NY

Live and Archived Webcast link:

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site or contact:

Dennis S. Dobson Jr., 203-258-0159

Jack Talley , CEO 
Actinium Pharmaceuticals Inc. 

Tel:  (646) 459-4201 



Jeff Ramson  
CEO of ProActive Capital Group, LLC 

Tel:  (646) 863-6341 


Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
2. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
3. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
4. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
5. Actinium Pharmaceuticals Announces New Round of Financing
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
8. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
9. Actinium Pharmaceuticals Strengthens Management Team
10. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
11. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
Post Your Comments:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):